Content about ViiV Healthcare

February 19, 2013
FDA grants priority review to ViiV drug for HIV

The Food and Drug Administration has granted priority review to an experimental drug made by ViiV Healthcare for HIV, the company, a joint venture between British drug maker GlaxoSmithKline and American drug maker Pfizer, announced.

LONDON — The Food and Drug Administration has granted priority review to an experimental drug made by ViiV Healthcare for HIV, the company, a joint venture between British drug maker GlaxoSmithKline and American drug maker Pfizer, announced.

The FDA gave the designation to dolutegravir, designed for use in combination with other antiretrovirual drugs in adults and adolescents. The agency gives priority review to drugs that offer significant improvement compared with products already on the market.

December 18, 2012
FDA approves generic HIV drug

The Food and Drug Administration has approved two generic versions of a drug to treat HIV, according to agency records.

SILVER SPRING, Md. — The Food and Drug Administration has approved two generic versions of a drug to treat HIV, according to agency records.

The FDA approved abacavir sulfate tablets in the 300-mg strength made by Apotex and Aurobindo.

The drug is a generic version of Viiv Healthcare's Ziagen.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.